SARS-CoV-2 mRNA-vaccine candidate; COReNAPCIN^®, induces robust humoral and cellular immunity in mice and non-human primates.

ABSTRACT: At the forefront of biopharmaceutical industry, the messenger RNA (mRNA) technology offers a flexible and scalable platform to address the urgent need for world-wide immunization in pandemic situations. This strategic powerful platform has recently been used to immunize millions of people proving both of safety and highest level of clinical efficacy against infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here we provide preclinical report of COReNAPCIN^®; a vaccine candidate against SARS-CoV-2 infection. COReNAPCIN^® is a nucleoside modified mRNA-based vaccine formulated in lipid nanoparticles (LNPs) for encoding the full-length prefusion stabilized SARS-CoV-2 spike glycoprotein on the cell surface. Vaccination of C57BL/6 and BALB/c mice and

SUBMITTER: Alimohammadi R 

PROVIDER: S-EPMC9438359 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature